ライフサイエンスコーパス: flexible sigmoidoscopy

1 ce mortality: fecal occult blood testing and flexible sigmoidoscopy.

2 roximal colon following a positive screening flexible sigmoidoscopy.

3 nts with distal adenomas or cancers found at flexible sigmoidoscopy.

4 40 674 (71%) people underwent flexible sigmoidoscopy.

5 lonoscopies and are 10-fold less common with flexible sigmoidoscopy.

6 l occult blood testing (FOBT), but not about flexible sigmoidoscopy.

7 with the new Medicare reimbursement rate for flexible sigmoidoscopy.

8 could increase to approximately 9.5 million flexible sigmoidoscopies (95% CI, 8.4-10.5) and 22.4 mil

9 al occult blood test screening plus periodic flexible sigmoidoscopy about every 5 years for asymptoma

10 If flexible sigmoidoscopy alone had been performed, advance

11 eir lesions identified if they had undergone flexible sigmoidoscopy alone, as compared with 66.3 perc

12 d have been identified if they had undergone flexible sigmoidoscopy alone.

13 er additional life-year gained compared with flexible sigmoidoscopy alone.

14 approximately 2.8 million (95% CI, 2.4-3.1) flexible sigmoidoscopies and 14.2 million (95% CI, 12.1-

15 Approximately 2.8 million flexible sigmoidoscopies and 14.2 million colonoscopies

16 they could perform an additional 6.7 million flexible sigmoidoscopies and 8.2 million colonoscopies i

17 eening group (10,283 randomized to receive a flexible sigmoidoscopy and 10,289 to receive flexible si

18 ntervention group), 83.5% underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5

19 le sigmoidoscopy or combination of once-only flexible sigmoidoscopy and fecal occult blood testing (F

20 nce-only flexible sigmoidoscopy screening or flexible sigmoidoscopy and FOBT reduced colorectal cance

21 tween the flexible sigmoidoscopy only vs the flexible sigmoidoscopy and FOBT screening groups.

22 flexible sigmoidoscopy and 10,289 to receive flexible sigmoidoscopy and FOBT).

23 We created a new library of 57 videos of flexible sigmoidoscopy and stratified them based on dise

24 The strategies included conventional serial flexible sigmoidoscopy and two different APC gene testin

25 d performance of fecal occult blood testing, flexible sigmoidoscopy, and barium enema.

26 uctible health plan members had colonoscopy, flexible sigmoidoscopy, and DCBE less often (ratio of ch

27 ests subject to the deductible (colonoscopy, flexible sigmoidoscopy, and DCBE).

28 Incidence rates of colonoscopy, flexible sigmoidoscopy, and fecal occult blood test were

29 ced nurse endoscopists may perform screening flexible sigmoidoscopy as safely and as effectively as g

30 ven, performance of endoscopic ultrasound or flexible sigmoidoscopy at 3- to 6-month intervals for th

31 Participants received flexible sigmoidoscopy at baseline and 3 or 5 y after.

32 ategies included no evaluation, colonoscopy, flexible sigmoidoscopy, barium enema, anoscopy, or any f

33 The cost of flexible sigmoidoscopy-based screening for colorectal ca

34 ncer) in men would be missed with the use of flexible sigmoidoscopy but detected by colonoscopy.

35 he Medicare reimbursement rate for screening flexible sigmoidoscopy (code 45330, $87.84).

36 ently available methods (fecal occult blood, flexible sigmoidoscopy, colonoscopy, and double contrast

37 cal occult blood testing in the past year or flexible sigmoidoscopy, colonoscopy, or barium enema in

38 The incremental cost-effectiveness of flexible sigmoidoscopy compared with no evaluation or wi

39 effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography

40 INTERPRETATION: A single flexible sigmoidoscopy continues to provide substantial

41 Colonoscopy, flexible sigmoidoscopy, CTC, and stool tests have differ

42 negative individuals, use of colonoscopy and flexible sigmoidoscopy decreased significantly between p

43 iterature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal tes

44 s, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years.

45 Annual Hemoccult II and flexible sigmoidoscopy every 5 years alone were less eff

46 al occult blood testing (FOBT) combined with flexible sigmoidoscopy every 5 years and using colonosco

47 , annual screening with a sensitive FOBT, or flexible sigmoidoscopy every 5 years with a midinterval

48 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years, or colonoscopy eve

49 years and older who had a negative screening flexible sigmoidoscopy examination between 1994 and 1996

50 ore costly and less effective than FOBT plus flexible sigmoidoscopy, except in the CRC-SPIN model ass

51 Cost analysis of flexible sigmoidoscopy, followed by colonoscopy as warra

52 analyses have only reported follow-up after flexible sigmoidoscopy for a maximum of 12 years.

53 Flexible sigmoidoscopy (FS) is recommended for mass scre

54 f computed tomographic (CT) colonography and flexible sigmoidoscopy (FS) screening and the factors pr

55 yielded varying estimates of the benefit of flexible sigmoidoscopy (FS) screening for colorectal can

56 symptomatic subjects who underwent screening flexible sigmoidoscopy (FSG) within the Prostate, Lung,

57 d on the size of the abnormality detected at flexible sigmoidoscopy (FSG).

58 ible sigmoidoscopy with anoscopy followed by flexible sigmoidoscopy if needed, the middle 95th percen

59 Lesions were considered detectable by flexible sigmoidoscopy if they were in the distal colon

60 This study examines the cost of performing flexible sigmoidoscopy in a primary care practice and co

61 ore costly and less effective than FOBT plus flexible sigmoidoscopy in all three models in both 100%

62 Flexible sigmoidoscopy is a safe and practical test and,

63 The use of nurse endoscopists to perform flexible sigmoidoscopy is expanding, increasing the avai

64 cal colonoscopy beyond the expected reach of flexible sigmoidoscopy is very low and may not justify t

65 creening, although current techniques (e.g., flexible sigmoidoscopy) lack the requisite sensitivity.

66 Screening with flexible sigmoidoscopy may reduce mortality rates from c

67 al trials (RCTs) evaluating 1-time or 2-time flexible sigmoidoscopy (n = 458,002) were associated wit

68 We evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer incidence an

69 There was no difference between the flexible sigmoidoscopy only vs the flexible sigmoidoscop

70 The capacity for screening with flexible sigmoidoscopy or colonoscopy depends on the pro

71 s beginning at age 50, using either FOBT and flexible sigmoidoscopy or colonoscopy in each racial or

72 total of 8207 practices reported performing flexible sigmoidoscopy or colonoscopy in the United Stat

73 Poor patient attendance to scheduled flexible sigmoidoscopy or colonoscopy may contribute to

74 rs to screen the unscreened population using flexible sigmoidoscopy or colonoscopy.

75 nts were randomized 1:1 to receive once-only flexible sigmoidoscopy or combination of once-only flexi

76 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or colonoscopy screening beginni

77 -laxative computed tomographic colonography, flexible sigmoidoscopy, or colonoscopy).

78 lt blood testing (FOBT) but not colonoscopy, flexible sigmoidoscopy, or double-contrast barium enema

79 3: ACP recommends using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy as a scre

80 AP screening strategy depends on the cost of flexible sigmoidoscopy, patient age when screening start

81 atients were randomized to undergo screening flexible sigmoidoscopy performed by a nurse endoscopist

82 n, and the incidence of complications during flexible sigmoidoscopy performed by nurse endoscopists a

83 The incremental cost-effectiveness of flexible sigmoidoscopy plus barium enema compared with c

84 A strategy of flexible sigmoidoscopy plus barium enema yielded the gre

85 eline-concordant screening with colonoscopy, flexible sigmoidoscopy plus either sensitive unrehydrate

86 eports, 20,748 colonoscopy reports, and 9767 flexible sigmoidoscopy reports to the central databank.

87 nalyses is that the time required to perform flexible sigmoidoscopy represents an opportunity cost be

88 ancer incidence and mortality after a single flexible sigmoidoscopy screening and 17 years of follow-

89 55 to 74 years, randomly assigned to receive flexible sigmoidoscopy screening as part of the Prostate

90 We tested the hypothesis that only one flexible sigmoidoscopy screening between 55 and 64 years

91 In Norway, once-only flexible sigmoidoscopy screening or flexible sigmoidosco

92 Flexible Sigmoidoscopy Screening Trial (overall, 12.1%;

93 In this multicentre randomised trial (UK Flexible Sigmoidoscopy Screening Trial), done between No

94 gned (1:2) to an intervention group (offered flexible sigmoidoscopy screening) or a control group (no

95 allocated to the intervention group (offered flexible sigmoidoscopy screening) or the control group (

96 ho have a small tubular adenoma on screening flexible sigmoidoscopy should undergo colonoscopic exami

97 rectal and Ovarian cancer screening trial of flexible sigmoidoscopy versus usual care (55-74 years ol

98 Screening with flexible sigmoidoscopy was associated with a significant

99 The diagnostic yield of flexible sigmoidoscopy was calculated by estimating the

100 Flexible sigmoidoscopy was most commonly performed for r

101 Fecal occult blood testing or flexible sigmoidoscopy was ordered for 47.2% of interven

102 ociated with the performance of office-based flexible sigmoidoscopy were derived from the published l

103 Participants were examined by flexible sigmoidoscopy when the study began and then wer

104 probabilistic sensitivity analysis comparing flexible sigmoidoscopy with anoscopy followed by flexibl

105 ng evidence shows that periodic screening by flexible sigmoidoscopy with appropriate referral of pati

106 ursement may limit the adoption of screening flexible sigmoidoscopy with or without biopsy in primary

107 esting (FIT), multitarget stool DNA testing, flexible sigmoidoscopy with or without stool testing, co

108 screening of Americans 50 years and older by flexible sigmoidoscopy with referral of subjects with ad

109 to 74 years of age either to screening with flexible sigmoidoscopy, with a repeat screening at 3 or

110 es were used, the physician's total cost for flexible sigmoidoscopy without biopsy was $86.86, which

111 mental cost-effectiveness ratios ranged from flexible sigmoidoscopy yielding an increased life expect